

Figure 1




Figure 2





Figure 3






Figure 4

Figure 5

hlgK sequence diversity in VELOCIMMUNE® TdT mice




Figure 6

Rate of hIgK non-template additions in VELOCIMMUNE® TdT mice




Figure 7

(A) hIgK CDR3 length in VELOCIMMUNE® TdT mice




Figure 7 (Continued)

(B) Exonuclease Activity in VELOCIMMUNE® TdT mice





Figure 8

(A) V_k usage in VELOCIMMUNE[®] TdT mice



(B) J_k usage in VELOCIMMUNE® TdT mice




Figure 8 (Continued)

Figure 9

mlgλ sequence diversity in VELOCIMMUNE® TdT mice




Figure 10

Rate of mIgλ non-template additions in VELOCIMMUNE® TdT mice




Figure 11

mIgλ CDR3 length in VELOCIMMUNE® TdT mice




Figure 12

V_{λ} Usage in VELOCIMMUNE® TdT Mice




Figure 13

hlgK sequence diversity in Dual Light Chain TdT mice




Figure 14

Rate of mIgK non-template additions in Dual Light Chain TdT mice




Figure 15

mIgK CDR3 length in Dual Light Chain TdT mice




Figure 16

VK and JK Usage in Dual Light Chain TdT Mice

